Scientech Research LLC Has $1.87 Million Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Scientech Research LLC lowered its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,774 shares of the biopharmaceutical company’s stock after selling 372 shares during the quarter. Scientech Research LLC’s holdings in Regeneron Pharmaceuticals were worth $1,865,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in REGN. Gilbert & Cook Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 8.3% during the fourth quarter. Gilbert & Cook Inc. now owns 1,907 shares of the biopharmaceutical company’s stock valued at $1,675,000 after acquiring an additional 146 shares during the period. Congress Wealth Management LLC DE acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $271,000. Stifel Financial Corp increased its stake in Regeneron Pharmaceuticals by 34.3% in the 4th quarter. Stifel Financial Corp now owns 41,679 shares of the biopharmaceutical company’s stock valued at $36,606,000 after buying an additional 10,649 shares during the period. Focus Financial Network Inc. ADV acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $387,000. Finally, Avestar Capital LLC acquired a new position in Regeneron Pharmaceuticals in the 4th quarter valued at approximately $321,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total value of $105,924.00. Following the completion of the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, VP Jason Pitofsky sold 487 shares of the stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the completion of the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Arthur F. Ryan sold 100 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $1,059.24, for a total transaction of $105,924.00. Following the completion of the transaction, the director now owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The disclosure for this sale can be found here. Insiders sold a total of 9,270 shares of company stock valued at $10,695,833 in the last ninety days. Company insiders own 7.48% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on REGN shares. Leerink Partnrs lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday. Argus upped their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Truist Financial reiterated a “buy” rating and issued a $1,200.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Tuesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,200.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $1,118.62.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $1,039.96 on Friday. The company has a current ratio of 5.44, a quick ratio of 4.62 and a debt-to-equity ratio of 0.10. The company has a fifty day simple moving average of $1,129.33 and a 200 day simple moving average of $1,034.03. The company has a market cap of $114.59 billion, a P/E ratio of 30.72, a P/E/G ratio of 3.72 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a 1 year low of $769.19 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm had revenue of $3.55 billion during the quarter, compared to the consensus estimate of $3.38 billion. During the same period in the prior year, the firm earned $8.79 EPS. The business’s revenue was up 12.3% on a year-over-year basis. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.8 EPS for the current year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.